266 related articles for article (PubMed ID: 17356133)
21. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
22. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.
Sallmyr A; Fan J; Datta K; Kim KT; Grosu D; Shapiro P; Small D; Rassool F
Blood; 2008 Mar; 111(6):3173-82. PubMed ID: 18192505
[TBL] [Abstract][Full Text] [Related]
23. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
24. Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics.
Kellner F; Keil A; Schindler K; Tschongov T; Hünninger K; Loercher H; Rhein P; Böhmer SA; Böhmer FD; Müller JP
J Cell Mol Med; 2020 Apr; 24(8):4668-4676. PubMed ID: 32155324
[TBL] [Abstract][Full Text] [Related]
25. A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling.
Caldarelli A; Müller JP; Paskowski-Rogacz M; Herrmann K; Bauer R; Koch S; Heninger AK; Krastev D; Ding L; Kasper S; Fischer T; Brodhun M; Böhmer FD; Buchholz F
Leukemia; 2013 Dec; 27(12):2301-10. PubMed ID: 23508117
[TBL] [Abstract][Full Text] [Related]
26. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.
Qu S; Liu B; Guo X; Shi H; Zhou M; Li L; Yang S; Tong X; Wang H
Cancer; 2014 Jul; 120(14):2130-41. PubMed ID: 24737397
[TBL] [Abstract][Full Text] [Related]
27. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
28. The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation.
Marhäll A; Kazi JU; Rönnstrand L
Sci Rep; 2017 Oct; 7(1):13734. PubMed ID: 29062038
[TBL] [Abstract][Full Text] [Related]
29. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
[TBL] [Abstract][Full Text] [Related]
30. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
31. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
32. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
[TBL] [Abstract][Full Text] [Related]
33. FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.
Oellerich T; Mohr S; Corso J; Beck J; Döbele C; Braun H; Cremer A; Münch S; Wicht J; Oellerich MF; Bug G; Bohnenberger H; Perske C; Schütz E; Urlaub H; Serve H
Blood; 2015 Mar; 125(12):1936-47. PubMed ID: 25605370
[TBL] [Abstract][Full Text] [Related]
34. The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia.
Cao T; Jiang N; Liao H; Shuai X; Su J; Zheng Q
Sci Rep; 2019 Aug; 9(1):12209. PubMed ID: 31434952
[TBL] [Abstract][Full Text] [Related]
35. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.
Scheijen B; Ngo HT; Kang H; Griffin JD
Oncogene; 2004 Apr; 23(19):3338-49. PubMed ID: 14981546
[TBL] [Abstract][Full Text] [Related]
36. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
[TBL] [Abstract][Full Text] [Related]
37. STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia.
Sueur G; Boutet A; Gotanègre M; Mansat-De Mas V; Besson A; Manenti S; Bertoli S
Sci Rep; 2020 Feb; 10(1):1906. PubMed ID: 32024878
[TBL] [Abstract][Full Text] [Related]
38. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Reindl C; Bagrintseva K; Vempati S; Schnittger S; Ellwart JW; Wenig K; Hopfner KP; Hiddemann W; Spiekermann K
Blood; 2006 May; 107(9):3700-7. PubMed ID: 16410449
[TBL] [Abstract][Full Text] [Related]
39. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
[TBL] [Abstract][Full Text] [Related]
40. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]